Search

Displaying results 4781 - 4790 of 8412 in total
  1. Drug

    OM85

    go.drugbank.com/drugs/DB16533
    Investigational

    OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity.

  2. Drug

    AAV-RPE65

    go.drugbank.com/drugs/DB18343
    Experimental

    AAV-RPE65 is an adenovirus associated viral vector serotype 5 containing the human RPE65 gene

  3. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.

  4. Drug

    Epirizole

    go.drugbank.com/drugs/DB08991
    Experimental

    Epirizole is an oral nonsteroidal anti-inflammatory drug (NSAID) used for muscle and joint pain.

  5. Drug

    Danofloxacin

    go.drugbank.com/drugs/DB11393
    ExperimentalVet approved

    Danofloxacin is an antibiotic agent from the family of the fluoroquinolones used in veterinary medicine.

  6. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH) . Mecasermin rinfabate is similar to DB01277 in tha...

  7. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expres...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    [L43942,L42975] Chlormadinone acetate continues to be used in other countries due to its high contraceptive efficacy and tolerability.[A254422,L33974]

  9. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  10. Drug

    Lasalocid

    go.drugbank.com/drugs/DB11423
    ExperimentalVet approved

    Lasalocid is an agent that presents antibacterial and coccidiostat activities. It is produced by strains of _Streptomyces lasaliensis_.